Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial

Pipe, Steven W., Collins, Peter W. ORCID: https://orcid.org/0000-0002-6410-1324, Dhalluin, Christophe, Kenet, Gili, Schmitt, Christophe, Buri, Muriel, Jiménez-Yuste, Victor, Peyvandi, Flora, Young, Guy, Oldenburg, Johannes, Mancuso, Maria Elisa, Kavakli, Kaan, Kiialainen, Anna, Deb, Sonia, Niggli, Markus, Chang, Tiffany, Lehle, Michaela and Fijnvandraat, Karin 2024. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial. Blood 14 , pp. 1355-1364. 10.1182/blood.2023021832

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (846kB) | Preview

Abstract

Subcutaneous emicizumab enables prophylaxis for people with hemophilia A (HA) from birth, potentially reducing risk of bleeding and intracranial hemorrhage (ICH). HAVEN 7 (NCT04431726) is the first clinical trial of emicizumab dedicated to infants, designed to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in those aged ≤12 months with severe HA without factor VIII (FVIII) inhibitors. Participants in this phase 3b trial received emicizumab 3 mg/kg maintenance dose every 2 weeks for 52 weeks and are continuing emicizumab during the 7-year long-term follow-up. Efficacy end points included annualized bleed rate (ABR): treated, all, treated spontaneous, and treated joint bleeds. Safety end points included adverse events (AEs), thromboembolic events (TEs), thrombotic microangiopathies (TMAs), and immunogenicity (anti-emicizumab antibodies [ADAs] and FVIII inhibitors). At primary analysis, 55 male participants had received emicizumab (median treatment duration: 100.3; range, 52-118 weeks). Median age at informed consent was 4.0 months (range, 9 days to 11 months 30 days). Model-based ABR for treated bleeds was 0.4 (95% confidence interval, 0.30–0.63), with 54.5% of participants (n = 30) having zero treated bleeds. No ICH occurred. All 42 treated bleeds in 25 participants (45.5%) were traumatic. Nine participants (16.4%) had ≥1 emicizumab-related AE (all grade 1 injection-site reactions). No AE led to treatment changes. No deaths, TEs, or TMAs occurred. No participant tested positive for ADAs. Two participants were confirmed positive for FVIII inhibitors. This primary analysis of HAVEN 7 indicates that emicizumab is efficacious and well tolerated in infants with severe HA without FVIII inhibitors.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	American Society of Hematology
ISSN:	0006-4971
Date of First Compliant Deposit:	24 January 2024
Date of Acceptance:	6 December 2023
Last Modified:	29 Apr 2024 13:53
URI:	https://orca.cardiff.ac.uk/id/eprint/165809

Actions (repository staff only)

Edit Item